Agios Pharmaceuticals, Inc.
US ˙ NasdaqGS ˙ US00847X1046

SecurityAGIO / Agios Pharmaceuticals, Inc.
InstitutionRYDEX VARIABLE TRUST - Biotechnology Fund Variable Annuity
Latest Disclosed Ownership1,703 shares
Latest Disclosed Value $ 56,641
RYDEX VARIABLE TRUST - Biotechnology Fund Variable Annuity reports 5.07% decrease in ownership of AGIO / Agios Pharmaceuticals, Inc.

On August 27, 2025 - RYDEX VARIABLE TRUST - Biotechnology Fund Variable Annuity filed a NPORT-P form disclosing ownership of 1,703 shares of Agios Pharmaceuticals, Inc. (US:AGIO) valued at $56,642 USD as of June 30, 2025. The entity filed a previous NPORT-P on May 29, 2025 disclosing 1,794 shares of Agios Pharmaceuticals, Inc.. This represents a change in shares of -5.07% during the quarter. The current value of the position is $49,029 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2025-08-27 2025-06-30 NP Agios Pharmaceuticals EC US00847X1046 1,703 -91 -5.07 57 7.69 0.6295
2025-05-29 2025-03-31 NP Agios Pharmaceuticals EC US00847X1046 1,794 502 38.85 53 23.81 0.5584
2025-03-03 2024-12-31 NP Agios Pharmaceuticals EC US00847X1046 1,292 -4,438 -77.45 42 -79.00 0.4256
2020-11-25 2020-09-30 NP Agios Pharmaceuticals EC US00847X1046 5,730 528 10.15 201 -28.06 0.8370
2020-08-27 2020-06-30 NP Agios Pharmaceuticals EC US00847X1046 5,202 328 6.73 278 61.63 1.1212
2020-06-01 2020-03-31 NP Agios Pharmaceuticals EC US00847X1046 4,874 -310 -5.98 173 -30.36 1.0585
2020-03-02 2019-12-31 NP Agios Pharmaceuticals EC US00847X1046 5,184 -120 -2.26 248 44.44 1.1458
2019-11-27 2019-09-30 NP Agios Pharmaceuticals EC US00847X1046 5,304 5,304 172 0.9117
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.